Abstract
The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Current Pharmaceutical Biotechnology
Title:Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Volume: 17 Issue: 8
Author(s): Neha N. Parayath, Hayley Nehoff, Sebastien Taurin and Khaled Greish
Affiliation:
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Abstract: The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Export Options
About this article
Cite this article as:
N. Parayath Neha, Nehoff Hayley, Taurin Sebastien and Greish Khaled, Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/1389201017666160401145608
DOI https://dx.doi.org/10.2174/1389201017666160401145608 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endogenous BMP-4/ROS/COX-2 Mediated IPC and Resveratrol Alleviated Brain Damage
Current Pharmaceutical Design Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design Quantification of Intracellular Proteins and Monitoring Therapy Using Flow Cytometry
Current Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study
Current Alzheimer Research Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Pluripotency-Regulating Networks Provide Basis for Reprogramming
Current Molecular Medicine Synthesis, Cytotoxicity and Docking Simulation of Novel Annulated Dihydroisoquinoline Heterocycles
Mini-Reviews in Medicinal Chemistry Applications of Molecular Imaging in Drug Discovery and Development Process
Current Pharmaceutical Biotechnology The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design